BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15630779)

  • 1. Enfuvirtide doubles chances for suppression.
    AIDS Patient Care STDS; 2004 Sep; 18(9):550. PubMed ID: 15630779
    [No Abstract]   [Full Text] [Related]  

  • 2. The optimal use of enfuvirtide.
    Gallant JE
    Hopkins HIV Rep; 2003 May; 15(3):1-3. PubMed ID: 12809103
    [No Abstract]   [Full Text] [Related]  

  • 3. Enfuvirtide access, administration, and patient education.
    Celano SA
    Hopkins HIV Rep; 2003 May; 15(3):1, 12. PubMed ID: 12809102
    [No Abstract]   [Full Text] [Related]  

  • 4. T-1249 development suspended.
    Huff B
    GMHC Treat Issues; 2003 Dec; 17(12):6. PubMed ID: 15011643
    [No Abstract]   [Full Text] [Related]  

  • 5. Darunavir offers potent new combo when used with enfuvirtide in ritonavir-boosted regimen.
    Edmunds-Ogbuokiri T
    HIV Clin; 2007; 19(1):1-3. PubMed ID: 17405221
    [No Abstract]   [Full Text] [Related]  

  • 6. Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks.
    Sayana S; Prosser P; Ricaurte JC; Sanchez S; Hamwi G; Hershey-Weber J; Chien C; Easley A; Nguyen T; Wilson L; Khanlou H
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(2):85-6. PubMed ID: 19369697
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of darunavir and enfuvirtide in a pregnant woman.
    Sued O; Lattner J; Gun A; Patterson P; Abusamra L; Cesar C; Fink V; Krolewiecki A; Cahn P
    Int J STD AIDS; 2008 Dec; 19(12):866-7. PubMed ID: 19050223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients.
    Salzberger B; Däumer M; Gute P; Jaeger H; Knechten H; van Lunzen J; Mauss S; Mayr C; Moll A; Plettenberg A; Rockstroh J; Staszewski S; Stellbrink HJ; Stoll M; Sturmer M
    Eur J Med Res; 2007 Mar; 12(3):93-102. PubMed ID: 17507306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New partnership calls for clinical testing of two fusion inhibitors.
    Slovick J
    Posit Living; 1999 Aug; 8(7):15, 62. PubMed ID: 12492078
    [No Abstract]   [Full Text] [Related]  

  • 10. [Enfuvirtide. Two injections per day for HIV].
    Taéron C
    Rev Infirm; 2004 Oct; (104):35-6. PubMed ID: 15581312
    [No Abstract]   [Full Text] [Related]  

  • 11. Enfuvirtide (Fuzeon).
    Proj Inf Perspect; 2003 Oct; (36):4-5. PubMed ID: 14696566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enfuvirtide beneficial in experienced patients.
    AIDS Patient Care STDS; 2004 Jan; 18(1):57. PubMed ID: 15080095
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical trials for enfuvirtide (Fuzeon, T-20).
    Crabb C
    AIDS; 2003 Nov; 17(17):N13-4. PubMed ID: 15065580
    [No Abstract]   [Full Text] [Related]  

  • 14. Postmarketing use of enfuvirtide in veterans: provider compliance with criteria for use, overall efficacy, and tolerability.
    Belperio PS; Mole LA; Halloran J; Boothroyd DB; Thomas IC; Backus LI
    Ann Pharmacother; 2008 Nov; 42(11):1573-80. PubMed ID: 18940919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with a new fusion inhibitor: patient issues with enfuvirtide (T-20). A review of the presentation at the satellite symposium "New hope: advancing care in HIV infection" at the 15th annual Association of Nurses in AIDS Care conference, November 2002.
    Glutzer E
    AIDS Read; 2003 Mar; 13(3 Suppl):S14-6. PubMed ID: 12765161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fuzeon treatment forum, January 2004.
    Burgess GE
    Surviv News (Atlanta Ga); 2004; 15(1):10. PubMed ID: 15032144
    [No Abstract]   [Full Text] [Related]  

  • 17. A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtide.
    Beatty G; Hunt P; Smith A; Hoh R; Huang W; Martin J; Deeks SG
    Antivir Ther; 2006; 11(3):315-9. PubMed ID: 16759047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New drug class blocks virus-cell fusion. HIV not admitted].
    MMW Fortschr Med; 2003 Sep; 145(35-36):53. PubMed ID: 14584215
    [No Abstract]   [Full Text] [Related]  

  • 19. First-line use of enfuvirtide-containing HAART regimen with dramatic clinical and immunological improvement in three cases.
    Bourgarit A; Lascoux C; Palmer P; Tuleja E; Pintado C; Farge D; Sereni D
    AIDS; 2006 Feb; 20(3):471-3. PubMed ID: 16439888
    [No Abstract]   [Full Text] [Related]  

  • 20. The importance of sequencing in treatment options.
    Berger DS
    Posit Aware; 2001; 12(3):42-3. PubMed ID: 11686121
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.